-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Minimed Group, Raises Price Target to $28

Benzinga·10/08/2026 12:47:08
语音播报
Mizuho analyst Anthony Petrone maintains Minimed Group (NASDAQ:MMED) with a Outperform and raises the price target from $26 to $28.